Empagliflozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2). SGLT2 is the predominant transporter responsible for the reabsorption of glucose from the kidney back into the circulation. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion. Hence, glucose is released through urine and decreases HbA1c level. As SGLT2 is a co-transporter, sodium & water also excrete with glucose through urine. So, decrease BP.